GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (OTCPK:CTRVW) » Definitions » 3-Year EPS without NRI Growth Rate

Hepion Pharmaceuticals (Hepion Pharmaceuticals) 3-Year EPS without NRI Growth Rate : 35.30% (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Hepion Pharmaceuticals 3-Year EPS without NRI Growth Rate?

Hepion Pharmaceuticals's EPS without NRI for the three months ended in Mar. 2024 was $0.00.

During the past 3 years, the average EPS without NRI Growth Rate was 35.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 63.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 11 years, the highest 3-Year average EPS without NRI Growth Rate of Hepion Pharmaceuticals was 84.80% per year. The lowest was -41.40% per year. And the median was 55.00% per year.


Competitive Comparison of Hepion Pharmaceuticals's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Hepion Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hepion Pharmaceuticals's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Hepion Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.



Hepion Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Hepion Pharmaceuticals  (OTCPK:CTRVW) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Hepion Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
399 Thornall Street, First Floor, Edison, NJ, USA, 08837
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.